Walking with age becomes both slower and less 'automated', requiring more attention and brain resources. As a result, older adults have a greater risk of negative outcomes and falls. There is an urgent need to identify factors that can help compensate for these harmful factors and reduce walking impairments, as there are currently no effective treatments available. Investigators have recently discovered that
20% of older adults maintain fast walking speed even in the presence of small blood vessel brain changes and leg problems, thus appearing to be protected against these harmful factors. The investigators work suggests that the brain dopamine (DA) system may be a source of this protective capacity. Investigators have also shown that lower levels of dopamine are associated with slow walking. Investigators will be investigating the role of dopamine on slow walking and other parkinsonian signs in this open-label study using detailed clinical assessment, assessment of dopamine activity, and clinical interventions.

开始日期2024-10-29

申办/合作机构

University of Michigan

[+1]

NCT06626152

/ Recruiting临床2期IIT

Measuring Psychomotor Response to L-DOPA Challenge As a Biomarker for Outcomes in Late-Life Depression: a Pilot Feasibility Trial

Background
Adults over the age of 60 with symptoms of major depressive disorder are said to have late-life depression (LLD), a condition that usually decreases a person's quality of life and is associated with other risks like physical frailty and dementia. A common feature of more severe LLD is psychomotor slowing, where a person's ability to think and move are impaired. For example, they might not be able to walk or process information as quickly, and they might have problems with their working memory.
Psychomotor slowing in LLD might be the result of a problem with the way a person's body produces or responds to the neurotransmitter dopamine. The drug Levodopa (L-DOPA), which can replace missing dopamine in the brain, has been used to treat to treat Parkinson's disease for many decades, and it might also affect psychomotor slowing in LLD.
Methods
In this study, participants are adults aged 60 years or older with moderate to severe major depression. Participants undergo the "L-DOPA challenge"-a 2-week period where they receive a dose of L-DOPA once a day for the first week and a dose of L-DOPA twice a day for the second week. Before and after a participant completes the L-DOPA challenge, the study team assesses their depressive symptoms and psychomotor function. After the L-DOPA challenge, if a participant still shows signs of moderate or severe depression, they receive an antidepressant for 12 weeks.
Aims
The first aim of this study is to test the feasibility of the L-DOPA challenge-that is, whether most of the 50 participants recruited for this study will complete the L-DOPA challenge. For example, participants might have to withdraw if they can't make the daily visits to the research site to receive their L-DOPA medication, if they can't tolerate the medication's side effects, or if their depressive symptoms get significantly worse. Our hypothesis is that 80% of the participants will complete the L-DOPA challenge.
The second aim of the study is to see if L-DOPA affects participants' depressive symptoms, processing speed, and working memory. Our hypothesis is that L-DOPA response, measured as an improvement in gait speed, is associated with a decrease in depressive symptoms and an increase in processing speed and working memory.

开始日期2024-08-15

申办/合作机构

University of British Columbia

[+1]

NCT06219915

/ Completed临床1/2期IIT

Neurobiological Drivers of Mobility Resilience: The Dopaminergic System

Walking with age becomes both slower and less 'automated', requiring more attention and brain resources. As a result, older adults have a greater risk of negative outcomes and falls. There is an urgent need to identify factors that can help compensate for these harmful factors and reduce walking impairments, as there are currently no effective treatments available. Investigators have recently discovered that
20% of older adults maintain fast walking speed even in the presence of small blood vessel brain changes and leg problems, thus appearing to be protected against these harmful factors. The investigators work suggests that the brain dopamine (DA) system may be a source of this protective capacity. Investigators have also shown that lower levels of dopamine are associated with slow walking. Investigators will be investigating the role of dopamine on slow walking and other parkinsonian signs in this double-blinded, placebo-controlled study using detailed clinical assessment, assessment of dopamine activity, and clinical interventions.

开始日期2024-03-15

申办/合作机构

University of Michigan

[+1]

100 项与卡比多巴相关的临床结果

登录后查看更多信息

100 项与卡比多巴相关的转化医学

登录后查看更多信息

100 项与卡比多巴相关的专利（医药）

登录后查看更多信息

3,646

项与卡比多巴相关的文献（医药）

2025-04-01·The Neurohospitalist

Acute Ischemic Stroke Presenting as Hemiparkinsonism: A Case Report

Article

作者: Al-Sibahee, Essam ; Al-Obaidi, Mustafa Najah ; Al-Sharee, Asmaa

Parkinsonism, commonly associated with Parkinson disease (PD), can also arise from other neurodegenerative disorders or non-neurodegenerative causes such as vascular parkinsonism (VP). This case highlights the acute onset of VP following a stroke, contributing to the understanding of VP’s varied presentations and the challenges in its diagnosis. A 54-year-old male with a history of cerebrovascular disease presented with behavioral changes and reduced activity, initially raising the suspicion of a central nervous system infection. Clinical findings included agitation, decreased social interaction, mutism, drooling, immobility, and rigidity. Imaging revealed acute infarction in the left cortical parieto-occipital region, caudate nucleus, and putamen, along with old infarcts, confirming VP. The primary diagnosis was vascular parkinsonism and he was started on anticoagulation therapy and levodopa/carbidopa, which showed minimal improvement over 6 months. This case underscores the importance of considering VP in patients with acute parkinsonian symptoms and a history of cerebrovascular disease. It highlights the necessity for prompt evaluation and management of vascular risk factors to optimize patient outcomes. Additionally, it emphasizes the need for a multidisciplinary approach in treating VP, given the limited efficacy of traditional Parkinson disease medications.

2025-03-04·Expert Opinion on Drug Metabolism & Toxicology

Clinical pharmacokinetics of levodopa and relevant add-on therapies for Parkinson’s disease

Review

作者: Müller, Thomas

INTRODUCTIONParkinson's disease is a chronic neurodegenerative disease entity characterized by heterogeneity of symptoms and progression. Levodopa is an efficacious and well tolerated dopamine substituting drug for its therapy. Its O-methylation and generation of 3-O-methyldopa is enhanced by levodopa/dopa decarboxylase inhibitor formulations. Additional inhibition of catechol-O-methyltransferase is the relevant add on therapy for levodopa application. This pharmacologic approach increases the plasma appearance of levodopa and reduces 3-O-methyldopa synthesis. Available marketed compounds are entacapone, tolcapone and opicapone. Data on their effects on levodopa pharmacokinetics in patients are rare.AREAS COVEREDThis review describes the impact of this add-on therapy on the pharmacokinetic profile of levodopa and 3-O-methyldopa in plasma. The rationale was to perform a comparison with data from previously published pharmacokinetic trials with a standardized one time intake of levodopa/carbidopa without and with the available catechol-O-methyltransferase inhibitors.EXPERT OPINIONResults of this analysis identified opicapone as the most efficacious inhibitor of catechol-O-methyltransferase in terms of changes of levodopa plasma concentrations. Opicapone induced higher levodopa plasma levels compared with the ones following application of levodopa/carbidopa alone or combined with entacapone or tolcapone. Co-administration of opicapone with its once daily intake regimen may support the efficacy of subcutaneous and intrajejunal levodopa infusions.

2025-03-01·Brain, Behavior, and Immunity

Sustained effects of repeated levodopa (L-DOPA) administration on reward circuitry, effort-based motivation, and anhedonia in depressed patients with higher inflammation

Article

作者: Miller, Andrew H ; Ashchi, Andrea ; Bekhbat, Mandakh ; Dunlop, Boadie W ; Goldsmith, David R ; Treadway, Michael T ; Felger, Jennifer C ; Li, Zhihao ; Revill, Kate P ; Wommack, Evanthia C ; Hong, Changdo ; Lucido, Michael J ; Haroon, Ebrahim ; Mehta, Neeti D

Inflammatory biomarkers like C-reactive protein (CRP) are elevated in a subset of patients with depression and have been associated with lower functional connectivity (FC) in a ventral striatum (VS) to ventromedial prefrontal cortex (vmPFC) reward circuit and symptoms of anhedonia. Evidence linking these relationships to the effects of inflammation on dopamine is consistent with our recent findings that acute levodopa (L-DOPA) increased VS-vmPFC FC in association with deceased anhedonia in depressed patients with higher but not lower CRP (>2 versus ≤ 2 mg/L). To determine whether repeated L-DOPA administration caused sustained effects on FC and behavior in these patients, medically stable depressed outpatients with CRP > 2 mg/L and anhedonia (n = 18) received one week of three doses of L-DOPA (150-450 mg/day/week with carbidopa) or placebo in a randomized order. Resting-state (rs) and task-based (tb; monetary incentive delay) fMRI, effort-based motivation, and exploratory measures of anhedonia and depression severity were assessed at baseline and after one week of placebo and each dose of L-DOPA. Responses to individual doses of L-DOPA varied across outcomes. For example, VS-vmPFC rs-FC was significantly increased by L-DOPA at 150 and 450 mg/day/week (p < 0.01), whereby approximately half of patients responded optimally to 150 mg/day L-DOPA and approximately half required higher doses for maximum effect. While effort-based motivation was only significantly increased by L-DOPA at 150 mg/day (p < 0.05), it correlated with VS-vmPFC rs-FC at this dose (r = 0.64, p = 0.024), and all L-DOPA doses met a clinically significant threshold of ≥ 10 % increase versus placebo. When comparing the maximum response at any L-DOPA dose to placebo, high effect sizes were observed for these primary outcomes and tb-FC during reward anticipation (d_z = 0.82-0.98, p < 0.01), as well as secondary and exploratory measures of anhedonia and depression severity (d_z = 0.48-0.97, p < 0.05). Sustained effects on reward circuitry, effort-based motivation, and anhedonia by repeated L-DOPA administration support the therapeutic potential of agents that increase dopamine in depressed patients with higher inflammation.

242

项与卡比多巴相关的新闻（医药）

2025-02-06

·Pharmaceutical Technology

Supernus wins FDA approval for Parkinson’s pump on fourth try

Onapgo is approved for adult Parkinson’s patients experiencing motor fluctuations. Credit: Inside Creative House via Getty Images. Supernus Pharmaceuticals has won US approval for its wearable pump Onapgo (apomorphine hydrochloride) to treat symptoms of Parkinson’s disease. Supernus’ regulatory path for Onapgo has been marked by multiple setbacks over nearly five years, with the Food and Drug Administration (FDA) rejecting three prior applications before securing approval. The company acquired Onapgo, previously known as SPN-830, from US WorldMeds in 2020. Soon after, Supernus submitted its first application for FDA review. However, in 2020, the agency issued a refusal-to-file (RTF) letter, determining that the submission was incomplete and not ready for formal review. Supernus resubmitted the application twice, receiving complete response letters (CRLs) both times. The first 2022 rejection required further analysis of the infusion device and drug product, while the most recent CRL, issued in April 2023, cited product quality concerns and deficiencies in the master file for the proprietary pump. The company resubmitted its fourth application in August, leading to the current approval. Onapgo will now be available for adult Parkinson’s disease patients experiencing motor fluctuations. The wearable pump is designed to provide a continuous subcutaneous infusion of Supernus’ apomorphine (Apokyn). The drug is intended for patients experiencing “off” periods, where medication wears off and symptoms return or worsen. The approval is based on a Phase III, 12-week study (NCT02006121) involving 107 patients. Onapgo led to a drop in daily “off” time and an increase in daily good “on” time, defined as periods without dyskinesia and the patient’s global impression of change (PGIC). Supernus plans to launch Onapgo in the second quarter of 2025, supported by a team of specialists, a nurse education programme, and access support services. The approval adds Onapgo to a growing list of infusion-based Parkinson’s treatments. AbbVie ’s Vyalev (foscarbidopa and foslevodopa), a continuous subcutaneous infusion therapy combining prodrugs of carbidopa and levodopa, was approved in October 2024 after three regulatory attempts. The FDA’s initial rejection of Vyalev did not involve efficacy or safety concerns but requested additional information on the pump device. The second rejection followed findings of issues at a third-party manufacturer. AbbVie set a precedent in 2015 with its Parkinson’s disease infusion pump therapy Produodopa (foslevodopa foscarbidopa), sparking innovation in drug delivery systems as companies looked for alternatives for conventional oral treatments.

上市批准临床3期

2025-02-04

·FiercePharma

Supernus' 4th try proves the charm with long-awaited FDA approval for Parkinson's infusion pump Onapgo

Supernus Pharmaceuticals has been trying to push its Onapgo across the FDA finish line since 2020. Three strikes and you’re out? Not for Supernus Pharmaceuticals and its Parkinson’s disease infusion pump.On its fourth attempt to pass muster with the FDA, the company’s SPN-830, now branded as Onapgo, finally earned the agency’s stamp of approval to treat motor fluctuations in adults with advanced Parkinson’s.Onapgo is a wearable pump designed to provide a continuous subcutaneous infusion of Supernus’ apomorphine (Apokyn). The drug is meant to allow patients more control over their daily "off" time, or the instances when patients' medicine wears off and symptoms return or worsen. A continuous treatment like Onapgo can “help to make days with Parkinson’s more predictable,” Andrea Merriam, CEO of the Parkinson & Movement Disorder Alliance, explained in Supernus' press release on Tuesday.In a phase 3 study, the drug cut down on patients' daily "off" time after 12 weeks of treatment while also providing a significant increase in daily "good on" time, periods when medication works as intended and patients don't experience involuntary movements.Onapgo represents a “novel approach” for those with Parkinson’s motor fluctuations and showcases the company’s “continued commitment to developing novel alternatives to manage Parkinson’s disease and other neurological conditions,” CEO Jack Khattar said in the company's press release.Supernus is already gearing up for a launch and intends to make the drug available in the second quarter of this year. It’s been nearly a five-year journey to this point for Supernus after the company acquired the device and Apokyn from US WorldMeds in 2020. After quickly filing for approval, the FDA responded with a refuse-to-file notice, meaning that the agency didn’t have enough information to perform a thorough review.Then, in 2022, the FDA shut down the company’s second approval bid with a complete response letter requesting more information on the drug's labeling, manufacturing and other factors, Supernus disclosed at the time.Most recently, the agency again issued a complete response letter upon Supernus’ third approval try. In its rejection letter last year, the agency cited issues with product quality and the drug’s master file. While the fourth time proved the charm for Supernus, it took AbbVie and its continuous subcutaneous Parkinson’s pump three tries to finally cross the FDA finish line in October. That treatment, Vyalev, is made up of prodrugs of standard-of-care medicines carbidopa and levodopa. Supernus’ Apokyn contributed $19.9 million to the company’s total sales over the third quarter of 2024. In 2023, the drug pulled in $75.1 million in full-year sales.

临床3期上市批准临床结果

2025-01-23

·医药速览

盘点 | 2024年FDA新药获批：50款新药获批，肿瘤药占比最大

美国美国食品药品监督管理局（FDA）于2025年1月8日发布了其2024年度FDA新药审批总结报告（Novel Drug Approvals for 2024）。报告汇总了FDA药品审评与研究中心（CDER）2024一年中批准的所有新药、新用途和新使用人群以及生物类似药和可互换生物类似药、新配方和新剂型以及儿科人群扩展，概述了一系列值得注意的批准，提供了许多CDER批准的新治疗药物促进患者健康的有价值实例。Nature Reviews Drug Discovery发文对此年度新药批准情况进行了总结，本文详细梳理了这些新药的亮点，涵盖肿瘤、精神疾病、心血管疾病等关键治疗领域的突破性进展，以及一些备受瞩目的首次批准。图片来自FDA官网 50款新药获批，肿瘤药占据近1/3江山，小分子药物创新不断 2024年，FDA旗下的CDER在新药批准方面取得了显著成果，共批准了50种新药（具体清单详见：https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024），这一数字较2023年的55种有所下降，但过去10年的滚动平均批准数量达到了46.5种/年的新高（图1），包括小分子药物、生物制剂和寡核苷酸治疗药物。图1. 自1994年以来的FDA新药获批情况。不包含CBER负责的疫苗、细胞与基因疗法在这些新药中，肿瘤治疗领域占比最高，15种新药获批，占比高达30%，其中包括数种同类首创药物。此外，皮肤领域和非恶性血液病领域各有6种新药获批，并列第二，心血管领域也有5种新药获得绿灯。另外，神经发育疾病和感染性疾病相关批准数量有所下降，低于近年平均水平（图2）。图2. CDER按治疗领域批准情况。包括多个疾病领域的适应症仅根据FDA办公室和部门审查批准申请的情况进行分类。小分子药物仍在2024年仍占据主流，细胞和基因疗法批准数目创下历史新高。在CDER所有批准的药物中，小分子药物共32个，占比64%，与前5年的平均水平保持一致。生物药占32%，共16个，其中单抗10个，双抗仅3个（图3）。图3. CDER按药物类型批准情况。包括小分子药物，长度不超过40个氨基酸的肽，以及寡核苷酸被批准为新分子实体（NMEs）。部分申请被拒药物在2024年，FDA对部分药物申请亮起了红灯（表1）。其中，Lykos公司寄希望于其药物midomafetamine（MDMA）用于治疗创伤后应激障碍，却因面临多重困境而未能获批。独立顾问委员会对其临床数据的可靠性、试验设计中缺乏功能性盲法以及潜在的安全性风险提出了质疑，此外，该药物在临床开发过程中还被指控存在不当性行为，这些因素共同导致了FDA的拒绝决定。 Daiichi Sankyo与Merck & Co（默沙东）合作研发的HER3靶向抗体药物偶联物（ADC）patritumab deruxtecan，因第三方制造设施的问题未能通过FDA的审查。然而，分析师们对其未来前景仍持乐观态度，认为一旦重新提交申请，获批的可能性较大。 Regeneron的CD20×CD3双特异性抗体odronextamab，因验证性试验的入组状态和完成时间不符合要求，遭到了FDA的拒绝。但Regeneron并未气馁，后续重新提交了申请，并最终获得了批准。 AbbVie的ABBV-951，这是一种卡比多巴和左旋多巴的前药，起初也遭遇了拒绝。不过，通过二次申请，AbbVie最终成功获得了FDA的批准，为帕金森病患者带来了新的治疗选择。表1. 2024年部分被拒药物期待已久的首次批准 2024年，一些备受瞩目的新药获得了FDA的批准，为相关疾病治疗带来了新的希望。 ●精神分裂症新药Cobenfy Karuna和Bristol Myers Squibb的固定剂量组合药物xanomeline和trospium（Cobenfy）获批用于治疗精神分裂症。这一双重M1/M4型毒蕈碱乙酰胆碱受体激动剂为精神分裂症提供了数十年来的首个新作用机制。在两项关键的III期试验EMERGENT-2和EMERGENT-3中，该组合疗法显著降低了患者的阳性和阴性症状量表（PANSS）评分，显示出良好的疗效。 ●NASH药物Rezdiffra Madrigal的resmetirom（Rezdiffra）成为首个获批的非酒精性脂肪性肝炎（NASH）药物。作为一种口服甲状腺激素受体β（THRβ）激动剂，resmetirom在III期MAESTRO-NASH研究中显示出对NASH缓解和纤维化改善的积极效果，为NASH患者带来了新的治疗选择。 NASH这一术语是在20世纪80年代创造的，其特征是肝脏中脂肪的积累和炎症，导致纤维化，甚至在某些情况下导致肝衰竭。该病后来被重新命名为代谢功能障碍相关脂肪性肝炎（MASH）。 “这是该领域的一个重大‘欢呼时刻’。”参与该药物研发的弗吉尼亚联邦大学肝病学家Arun Sanyal表示。 ●TIL细胞疗法Amtagvi Iovance Biotherapeutics的lifileucel（Amtagvi）获得了FDA加速批准，用于治疗晚期皮肤癌。这一肿瘤浸润性淋巴细胞（TIL）细胞疗法在II期试验中显示出32%的总体反应率，为实体瘤治疗提供了新的思路。研究人员数十年来一直在为TIL细胞疗法治疗实体瘤建立依据。这些活体疗法是通过收获癌组织、分离其中的抗癌T细胞，然后在生物反应器中培养这些细胞，再重新输注给患者制成的。嵌合抗原受体（CAR）T细胞——从血液中提取并在体外工程化并在生物反应器中培养的T细胞——基于其在血液肿瘤中的显著活性超越了TILs。但由于CAR-T细胞在实体瘤治疗中仍面临挑战，TILs正在迎头赶上。 “这花了太长时间。”美国国家肿瘤研究所的Steven Rosenberg教授表示。综观2024年，FDA在药物研发领域呈现出稳健前行且富有进取态势的景象。众多的探索与尝试，孕育出诸多潜在的治疗机遇。特别是在实体瘤的T细胞疗法方面，取得了令人瞩目的快速进展；小分子药物的创新，则为一些棘手的肿瘤类型开辟了全新的治疗路径。参考文献： 1.https://www.fda.gov/media/184967/download?attachment 2.Mullard A. 2024 FDA approvals. Nat Rev Drug Discov. 2025 Jan 2. doi: 10.1038/d41573-025-00001-5. （声明：本文仅用作学术交流分享，如涉侵权，请私信或留言联系我们删除。） MedComm系列期刊介绍 MedComm-Oncology是由Wiley出版发行的开放获取期刊，MedComm(2023 IF 10.7)姐妹刊。期刊主要发表肿瘤学及交叉学科领域的基础、临床和转化研究，致力于揭示肿瘤致病分子机理，提出诊断和治疗新方法等。期刊主编由法国笛卡尔大学Guido Kroemer教授（欧洲科学院院士、中国工程院外籍院士）和四川大学华西医院生物治疗全国重点实验室黄灿华教授担任。 2024年免收稿件处理费，欢迎投稿！往期推荐小囊泡，大耐药—细胞外囊泡如何“武装”癌细胞以抵御药物打击？| MedComm-Oncology 表观遗传在癌症治疗中的应用 | MedComm-Oncology MedComm-Oncology | 综述脂肪酸及其代谢通路在肿瘤中的研究进展与治疗前景解锁癌症谜题：氧化应激与细胞衰老的关键角色与治疗契机 | MedComm-Oncology最新综述 EGFR-TKIs药代动力学研究新成果：阿美替尼的临床应用及EGFR-TKI研发新方向 | MedComm-Oncology 氧化应激驱动肿瘤转移：表观遗传机制与靶向治疗新进展 | MedComm-Oncology PTPRD基因，免疫治疗疗效预言家？| MedComm – Oncology 推荐阅读 01 MedComm（IF 10.7）和Molecular Biomedicine (IF 6.3) 影响因子再创新高 | 祝贺！ 02 祝贺！MedComm系列期刊11位编委和作者荣获2024年中华医学科技奖 03 祝贺！MedComm – Oncology期刊多名编委荣耀入选科睿唯安2024年“全球高被引科学家”榜单往期链接 “小小疫苗”养成记 | 医药公司管线盘点人人学懂免疫学 | 人人学懂免疫学（语音版）综述文章解读 | 文献略读 | 医学科普 | 医药前沿笔记 PROTAC技术 | 抗体药物 | 抗体药物偶联-ADC 核酸疫苗 | CAR技术 | 化学生物学温馨提示医药速览公众号目前已经有近12个交流群（好学，有趣且奔波于医药圈人才聚集于此）。进群加作者微信（yiyaoxueshu666）或者扫描公众号二维码添加作者，备注“姓名/昵称-企业/高校-具体研究领域/专业”，此群仅为科研交流群，非诚勿扰。简单操作即可星标⭐️医药速览，第一时间收到我们的推送 ①点击标题下方“医药速览” ②至右上角“...” ③点击“设为星标

疫苗基因疗法核酸药物上市批准寡核苷酸

100 项与卡比多巴相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00558	卡比多巴	N04BA03	DB00190

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
恶心	美国	Aton Pharma, Inc.	1977-04-25
帕金森病	美国	Aton Pharma, Inc.	1977-04-25
脑炎后帕金森病	美国	Aton Pharma, Inc.	1977-04-25
继发性帕金森病	美国	Aton Pharma, Inc.	1977-04-25
呕吐	美国	Aton Pharma, Inc.	1977-04-25

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT00983814 (ADD201, CTgov)	临床2期	注意缺陷障碍伴多动	20	Carbidopa+Droxidopa (Droxidopa+Carbidopa: Double-Blind)	鏇顧簾夢窪遞選積艱遞(築襯壓遞窪簾糧齋艱憲) = 願鏇簾糧壓蓋廠憲選網壓網鬱製願網製製齋選 (夢鬱膚鬱構餘鬱鏇淵製, 膚襯襯繭衊簾獵餘鏇餘 ~ 齋醖範艱窪鹽築鹹鏇壓) 更多	-	2024-04-18
				placebo+carbidopa+droxidopa (Placebo: Double-Blind)	鏇顧簾夢窪遞選積艱遞(築襯壓遞窪簾糧齋艱憲) = 夢網窪醖蓋製顧夢壓選壓網鬱製願網製製齋選 (夢鬱膚鬱構餘鬱鏇淵製, 齋獵壓夢膚鹽糧糧獵獵 ~ 廠積繭鬱鑰構簾鏇製餘) 更多
NCT02553265 (CarbiFD, CTgov)	临床2期	单纯自主神经功能衰竭 \| 家族性自主神经功能异常	22	Placebo (Placebo)	鹽鏇鏇齋願積憲膚選壓(構築繭廠獵齋鑰蓋鹹選) = 鏇蓋範夢鹹簾壓窪網憲簾鬱窪憲衊窪鬱淵願壓 (淵選蓋積簾壓範遞鏇憲, 餘築遞願衊構窪遞鹽顧 ~ 糧廠蓋鑰齋艱願醖壓繭) 更多	-	2022-02-09
				Carbidopa Low-Dose (Low-Dose Carbidopa)	鹽鏇鏇齋願積憲膚選壓(構築繭廠獵齋鑰蓋鹹選) = 糧夢願築構繭網築鬱壓簾鬱窪憲衊窪鬱淵願壓 (淵選蓋積簾壓範遞鏇憲, 願範襯鹽鑰願窪衊襯窪 ~ 顧構醖淵襯膚醖蓋餘鹽) 更多
NCT00685919 (CTgov)	临床2/3期	体位性心动过速综合征	32	Placebo (Healthy Participants Who Received Placebo as Treatment A or Treatment B)	憲鬱鑰選齋鬱構顧築鏇(鏇艱餘簾窪製艱窪膚構) = 構製積範製觸範醖膚鬱糧蓋衊築鬱積積憲襯夢 (醖鹽鏇壓鏇觸鬱網憲鬱, 膚願鹹憲膚膚範範壓餘 ~ 鹽積積窪鏇構糧淵齋壓) 更多	-	2021-09-20
				Carbidopa (Healthy Participants Who Received Carbidopa as Treatment A or Treatment B)	憲鬱鑰選齋鬱構顧築鏇(鏇艱餘簾窪製艱窪膚構) = 鹹鏇遞範鹽糧築顧膚鹹糧蓋衊築鬱積積憲襯夢 (醖鹽鏇壓鏇觸鬱網憲鬱, 鹹壓願淵窪憲糧構範鹽 ~ 夢繭衊膚鏇壓膚鑰糧糧) 更多
EANM2020	N/A	脑癌 18 F-FDOPA	-	Carbidopa premedication	遞鹽襯衊膚鬱顧製鬱築(築艱積願膚網窪觸壓獵) = 窪襯積鹽網糧襯夢衊艱遞蓋積餘醖膚繭廠夢鹽 (製憲遞製遞壓鏇壓淵醖 ) 更多	-	2020-09-18
				Carbidopa (No premedication)	遞鹽襯衊膚鬱顧製鬱築(築艱積願膚網窪觸壓獵) = 鑰壓鏇積繭醖觸簾齋淵遞蓋積餘醖膚繭廠夢鹽 (製憲遞製遞壓鏇壓淵醖 ) 更多
MDS2020	N/A	帕金森病	255	Carbidopa (10 mg)	(簾鹹製醖構淵遞範淵鏇) = 遞衊選襯獵繭獵顧糧範遞膚憲網廠醖淵鬱築繭 (齋製簾網廠簾築遞範鏇 )	积极	2020-09-12
				Benserazide (25 mg)	(簾鹹製醖構淵遞範淵鏇) = 餘鏇範獵積鏇鹹築觸膚遞膚憲網廠醖淵鬱築繭 (齋製簾網廠簾築遞範鏇 )
NCT03115827 (CTgov)	临床4期	帕金森病	15	Carbidopa+Droxidopa	繭淵顧廠夢願衊築淵窪(鏇遞廠壓顧夢鹹衊鹹餘) = 願遞鹽鹹壓鏇齋壓艱鹽醖齋夢蓋觸齋鑰夢艱壓 (淵鹹襯餘淵網壓鏇鏇鏇, 觸網繭廠餘醖膚構繭蓋 ~ 窪遞鹹遞憲夢鹽鏇範製) 更多	-	2020-01-27
MDS2016	N/A	-	-	Levodopa + Carbidopa	餘鏇構糧遞糧憲襯淵鹽(憲網襯製簾鹹廠糧築遞) = 製構齋淵鬱衊夢觸獵遞壓繭餘觸夢糧齋齋簾夢 (獵夢構範鑰廠製夢鏇膚 ) 更多	-	2016-06-19
				Saline	餘鏇構糧遞糧憲襯淵鹽(憲網襯製簾鹹廠糧築遞) = 醖鬱鏇醖廠憲衊膚窪積壓繭餘觸夢糧齋齋簾夢 (獵夢構範鑰廠製夢鏇膚 ) 更多
NCT01568073 (CTgov)	临床3期	帕金森病	600	Placebo+Carbidopa+Benserazide+Levodopa (Placebo)	製淵選窪築積範廠築廠(壓選膚網醖積繭積願範) = 鬱淵觸繭願醖觸遞範蓋鬱淵鹽鑰鑰廠築衊選鹹 (鬱餘窪鏇顧壓製衊壓鹽, 願膚鹽淵獵壓簾廠膚餘 ~ 願顧繭糧觸醖選觸獵淵) 更多	-	2015-01-08
				Carbidopa+Benserazide+Entacapone+Levodopa (Entacapone)	製淵選窪築積範廠築廠(壓選膚網醖積繭積願範) = 衊獵壓積鹽鬱廠鏇鏇鬱鬱淵鹽鑰鑰廠築衊選鹹 (鬱餘窪鏇顧壓製衊壓鹽, 遞膚積獵衊範顧簾憲醖 ~ 築獵構製齋艱範顧範憲) 更多